Switch theme
Sign up to access all valuation multiples
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
1985
7.1K+
LTM Revenue $4.1B
LTM EBITDA $1.3B
$14.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hologic has a last 12-month revenue (LTM) of $4.1B and a last 12-month EBITDA of $1.3B.
In the most recent fiscal year, Hologic achieved revenue of $4.0B and an EBITDA of $1.3B.
Hologic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hologic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1B | XXX | $4.0B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.2B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $1.2B | XXX | $931M | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $957M | XXX | $790M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $374M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hologic's stock price is $62.
Hologic has current market cap of $13.9B, and EV of $14.8B.
See Hologic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.8B | $13.9B | XXX | XXX | XXX | XXX | $4.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hologic has market cap of $13.9B and EV of $14.8B.
Hologic's trades at 3.7x EV/Revenue multiple, and 11.3x EV/EBITDA.
Equity research analysts estimate Hologic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hologic has a P/E ratio of 14.5x.
See valuation multiples for Hologic and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.9B | XXX | $13.9B | XXX | XXX | XXX |
| EV (current) | $14.8B | XXX | $14.8B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 12.0x | XXX | 14.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.5x | XXX | 16.7x | XXX | XXX | XXX |
| EV/FCF | 15.9x | XXX | 13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHologic's last 12 month revenue growth is 4%
Hologic's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Hologic's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hologic's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hologic and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hologic acquired XXX companies to date.
Last acquisition by Hologic was XXXXXXXX, XXXXX XXXXX XXXXXX . Hologic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hologic founded? | Hologic was founded in 1985. |
| Where is Hologic headquartered? | Hologic is headquartered in United States of America. |
| How many employees does Hologic have? | As of today, Hologic has 7.1K+ employees. |
| Who is the CEO of Hologic? | Hologic's CEO is Mr. Stephen P. Macmillan. |
| Is Hologic publicy listed? | Yes, Hologic is a public company listed on NAS. |
| What is the stock symbol of Hologic? | Hologic trades under HOLX ticker. |
| When did Hologic go public? | Hologic went public in 1990. |
| Who are competitors of Hologic? | Similar companies to Hologic include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Hologic? | Hologic's current market cap is $13.9B |
| What is the current revenue of Hologic? | Hologic's last 12 months revenue is $4.1B. |
| What is the current revenue growth of Hologic? | Hologic revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Hologic? | Current revenue multiple of Hologic is 3.6x. |
| Is Hologic profitable? | Yes, Hologic is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hologic? | Hologic's last 12 months EBITDA is $1.3B. |
| What is Hologic's EBITDA margin? | Hologic's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Hologic? | Current EBITDA multiple of Hologic is 11.1x. |
| What is the current FCF of Hologic? | Hologic's last 12 months FCF is $926M. |
| What is Hologic's FCF margin? | Hologic's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of Hologic? | Current FCF multiple of Hologic is 15.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
